Location:Room 4, Capital suite (level 3)
Pelvic lymph node dissection in urological cancer treatment is undertaken for both prostate cancer and bladder cancer. Urological patients that undergo pelvic lymph node dissection in addition to their treatmnet will be subjected to an increased risk of complications such as lymphoedema. This can cause significant morbidity as a result of skin infection, eczema, pain as well as psychological discomfort. This session aims to provide knowledge on detecting risk factors and early signs in patients at high risk of getting lymphoedema and how it can be prevented and treated.
In developed countries cancer is the most frequent cause of secondary lymphedema but there are emerging data about genetic susceptibility and new drugs’ side effects that increase the risk of developing lymphedema. It is widely accepted that the etiology of lymphedema is multifactorial and risk factors could contribute more or less depending on individual and enviromental patient context. Patient evaluation before and after treatment is a strategical step to identify patients at higher risk, to adopt primary prevention strategies (including less invasive surgical procedures such as videoscopic LND) and to promote early detection and early treatment onset (secondary prevention). A detailed medical history (focused to risk factors) and a general clinical examination are followed by body region volume measurement plus lymphedema stage assessment using standardized methods and by disability and quality of life evaluationt using validated scales and instruments.